Immunological consequences following splenectomy in patients with liver cirrhosis

YUSUKE HIRAKAWA1, TOSHIRO OGATA1,2*, TETSURO SASADA3,4*, TAKUTO YAMASHITA5, KYOGO ITOH3, HIROYUKI TANAKA1 and KOJI OKUDA1

1Department of Surgery, Kurume University School of Medicine, Kurume, Fukuoka 830-0011; 2Department of Surgery, St. Mary’s Hospital, Kurume, Fukuoka 830-8543; 3Cancer Vaccine Center, Kurume University, Kurume, Fukuoka 839-0863; 4Cancer Vaccine Center, Kanagawa Cancer Center, Yokohama, Kanagawa 241-8515; 5Biostatistics Center, Kurume University, Kurume, Fukuoka 830-0011, Japan

Received October 6, 2018; Accepted May 16, 2019

DOI: 10.3892/etm.2019.7640

Abstract. The immune status in patients with liver cirrhosis is generally impaired due to concomitant hypersplenism. As the spleen is the largest lymphoid organ, deleterious events resulting from splenectomy are of concern in these patients. However, the immunological consequences after splenectomy have not yet been fully elucidated. In the present study, the immune status after splenectomy was comprehensively examined. Splenectomy was performed in 11 patients with liver cirrhosis and hypersplenism, and the immune status in peripheral blood was examined and compared before and at 1, 3 and 6 months after splenectomy. Splenectomy significantly lowered the neutrophil-to-lymphocyte ratio, due to a surge in lymphocytes in the peripheral circulation at 3 and 6 months after splenectomy. The frequency of cluster of differentiation (CD)4+ T cells decreased after splenectomy, whereas the frequency of CD8+ T cells increased. Notably, the frequencies of the naïve and central memory subsets of CD4+ and CD8+ T cells decreased, whereas those of the effector memory subset trended upward. In addition, the frequencies of other immune cells such as γδ T cells, natural killer T cells and natural killer cells transiently increased, while inhibitory cells such as regulatory T cells and myeloid-derived suppressor cells significantly decreased. T-cell responses to viral- and tumor-associated antigens increased after splenectomy in five of eight and two of five patients, respectively. To the best of our knowledge, this is the first study to precisely examine the drastic changes of immunological phenotypes in peripheral blood after splenectomy in patients with cirrhosis. Our findings suggested that splenectomy in patients with cirrhosis may ameliorate the impaired immune status, possibly by reducing suppressive cells and enhancing the effector cell population and function, which could, at least in part, explain the mechanisms responsible for the clinical benefits of splenectomy.

Introduction

Patients with liver cirrhosis are generally regarded as immunocompromised (1). Not only does bacterial infection develop in 14.5 to 34.0% of patients with liver cirrhosis (2), but community-acquired infections are also frequently observed in patients with more advanced liver cirrhosis. Because the spleen is the largest lymphoid organ in the body with concentrated amounts of T and B cells, macrophages, and dendritic cells, splenectomy in patients with cirrhosis has produced concern over decreased tumor immunity and an elevated risk of infection, such as overwhelming pneumococcal sepsis (3-5).

Thrombocytopenia has been known to be an important factor that interferes with treatment of hepatocellular carcinoma and chronic liver diseases (6). We previously reported that splenectomy in patients with advanced cirrhosis corrected thrombocytopenia, improved liver function, reduced portal venous pressure, and allowed prolonged management of hepatocellular carcinoma (HCC) and hepatitis C virus (HCV) infection (7). Other researchers have also described the clinical benefits of splenectomy in the management of portal hypertension (8,9), HCC (10), and living-donor liver transplantation (11) among patients with liver cirrhosis. In addition, Zhang et al reported that synchronous splenectomy and hepatectomy improved the disease-free survival rate compared with hepatectomy alone (12). Although the clinical merits of splenectomy for patients with cirrhosis have been reported, the possible immunological advantages have not yet been fully explored.

In the present study, we examined the effects of splenectomy on the neutrophil-to-lymphocyte ratio (NLR), an indicator...
of systemic inflammation and cancer outcomes (13,14), and phenotypes of various immune cells among peripheral blood mononuclear cells (PBMCs). Immune responses against viral- and tumor-associated antigens were also assessed and compared before and after splenectomy. Our results suggested that splenectomy might ameliorate the impaired immune status in patients with liver cirrhosis, possibly by reducing suppressive cell fractions and enhancing the effector cell population and function, which could, at least in part, explain the mechanisms responsible for clinical benefits of splenectomy.

Patients and methods

Patients. Eleven patients with liver cirrhosis and hypersplenism underwent hand-assisted laparoscopic splenectomy at the Department of Surgery of Kurume University Hospital. Six patients were male and five were female, with a median age of 65 years (range, 44-75 years). Five and six patients were classified as having Child-Pugh class A and B liver disease, respectively. Ten patients were HCV-positive and the remaining patient had alcoholic cirrhosis. Six patients had HCC. We performed splenectomy in an attempt to either manage thrombocytopenia caused by hypersplenism and thus facilitate anti-HCC treatment by improving liver function (n=6) or to prevent further thrombocytopenia caused by interferon treatment in patients with HCV (n=5). The patients with HCC received simultaneous radiofrequency ablation to treat hepatic lesions. Because prevalence of portal thrombosis after splenectomy in patients with liver cirrhosis was high (7,15), we performed prophylactic anticoagulation using danaparoid sodium and warfarin potassium to prevent portal thrombosis after splenectomy, as previously reported (7).

Along with careful clinical observations, the white blood cell (WBC), lymphocyte, neutrophil, and platelet counts were measured in the peripheral blood before and at 1, 3, and 6 months after splenectomy. The NLR was defined as the absolute neutrophil count divided by the absolute lymphocyte count. The study was conducted in accordance with the provisions of the Declaration of Helsinki and was approved by the Institutional Review Board at Kurume University Hospital. Before surgery, possible undesirable outcomes were explained to all patients involved in the study, and written informed consent was obtained from all patients.

Immune cell phenotypes. Immune cell phenotypes were determined by flow cytometry. A total of 30 ml of peripheral blood was serially obtained immediately before and at 1, 3, and 6 months after splenectomy. PBMCs were isolated by density gradient centrifugation with the Ficoll-Paque Plus (GE Healthcare, Uppsala, Sweden) and frozen until analysis. After thawing, PBMCs (5x10⁵ cells) were suspended in phosphate-buffered saline (PBS) containing 2% fetal bovine serum (MP Biologicals, Solon, OH, USA) and incubated for 30 min on ice with the appropriate dilution of antibodies. For analysis of CD4⁺ and CD8⁺ T cells and their naïve/memory subsets, PBMCs were stained with mouse anti-human CD4, mouse anti-human CD8, mouse anti-human CCR7, and mouse anti-human CD45RA monoclonal antibodies (mAbs). Since the available combination between mAbs and fluorescent dyes was limited in this multicolor flow cytometry panel, we could not completely compensate the spectral overlap. Therefore, nonlinear gating lines were set by using control samples, as previously reported (16). For analysis of gamma-delta (γδ) T, natural killer T (NKT), and natural killer (NK) cells, PBMCs were stained with mouse anti-human TCR γδ, mouse anti-human CD3, mouse anti-human CD6, and mouse anti-human CD56 mAbs. For analysis of Treg cells, PBMCs were stained with mouse anti-human CD4, mouse anti-human CD25, and mouse anti-human FoxP3 mAbs using the One Step Staining Human Treg Flow™ Kit (BioLegend, San Diego, CA, USA). For analysis of granulocytic myeloid-derived suppressor cells (MDSCs), PBMCs were stained with mouse anti-human CD11b, mouse anti-human CD15, and mouse anti-human CD33 mAbs (17). All mAbs were from BioLegend except for the anti-CD15 mAb (BD Biosciences, San Diego, CA, USA). The samples were run on a FACSCanto II analyzer (BD Biosciences), and the frequencies of each of the immune subsets were analyzed using FlowJo ver. 10 software (Tree Star, Ashland, OR, USA).

Immune responses to antigen peptides. To evaluate immune cell function, T-cell responses against viral- or tumor-associated antigen peptides were evaluated by an interferon gamma (IFN-γ) Enzyme-Linked ImmunoSpot (ELISPOT) assay with PBMCs before and after splenectomy in the enrolled patients whose PBMCs were available for analysis. The viral-associated antigen peptide pool consisted of 23 different HLA class I-restricted peptides derived from cytomegalovirus, Epstein-Barr virus, or influenza virus (CEF, Mabtech, Nacka Strand, Sweden). The CEF peptide pool contained 2 HLA-A1-, 3 HLA-A2-, 3 HLA-A3-, 2 HLA-A11-, 1 HLA-A24-, 1 HLA-A68-, 2 HLA-B7-, 4 HLA-B8-, 2 HLA-B27-, 1 HLA-B35-, and 2 HLA-B44-restricted peptides. The tumor-associated antigen peptide pool consisted of 20 different HLA class I-restricted peptides (KRM-20) as reported previously (18). The KRM-20 peptide pool contained 5 HLA-A2-, 9 HLA-A24-, 3 HLA-A3 supertype-, 1 HLA-A24/A3 supertype-, and 2 HLA-A24/A3 supertype/A26-restricted peptides. PBMCs (1x10⁵ cells/well) were incubated in round 96-well microculture plates (Thermo Fisher Scientific, Rochester, NY, USA) with 200 µl of medium (OptiMizer T Cell Expansion SFM; Life Technologies, Carlsbad, CA, USA) containing 10% fetal bovine serum (MP Biologicals), interleukin 2 (20 IU/ml; AbD Serotec, Kidlington, UK), and the peptide pools (CEF, 2 µg/ml; KRM-20, 10 µg/ml) for 7 days. After incubation, the cells (1-2x10⁴ cells/well) were harvested and tested for their ability to produce IFN-γ in response to the corresponding peptide pool (CEF, 2 µg/ml; KRM-20, 10 µg/ml). Antigen-specific IFN-γ secretion after 18 h of incubation was determined by the ELISPOT assay in accordance with the manufacturer's instructions (Mabtech), and spots were counted by an ELISPOT reader (CTL ImmunoSpot S5 Series; Cellular Technology, Ltd., Shaker Heights, OH, USA). Antigen-specific T-cell responses were evaluated by the difference between the numbers of spots produced in response to each corresponding peptide pool and those produced without it.

Statistical analysis. Data are expressed as mean or median with standard deviation. The paired Student's t-tests was used.
Figure 1. Alterations in lymphocytes and neutrophils following splenectomy. (A) Percentages of lymphocytes and neutrophils in the white blood cell counts before and after splenectomy. (B) Neutrophil-to-lymphocyte ratio before and after splenectomy. The data are presented as the mean ± standard deviation. The percentages or ratios at the indicated time points after splenectomy were compared with those before splenectomy. *P<0.05 by paired Student’s t-test compared with the data before splenectomy.

for comparison of percentages of lymphocytes and neutrophils in the WBC counts, neutrophil-to-lymphocyte ratios and immune cell phenotypes determined by flow cytometry. Since these analyses were exploratory, but not confirmatory, paired Student's t-tests was employed without considering adjustment of multiplicity. The Wilcoxon signed rank test was used for comparison of spot numbers of antigen-specific T cells determined by ELISPOT assay. A two-sided significance level of 5% was considered statistically significant in all analyses. Statistical analyses were performed using SAS software version 9.4 (SAS Institute, Cary, NC).

Results

Clinical outcomes. The average weight of the excised spleen was 522±211 g. The average blood loss volume was 82±187 ml, and the average operation time was 235±74 min. Postoperative complications were portal thrombosis (n=1), ascites (n=1), bacterial colitis (n=1), and fever (n=1). Portal thrombosis was treated with anticoagulants. Bacterial infection and ascites were successfully treated with antibiotics and diuretics, respectively. No patients had fatal complications. Patients were discharged at 14±2.6 days.

The average platelet count before splenectomy was 4.9±1.6x10^9/mm^3, and the average WBC count was 2633±947/mm^3. Although the neutrophil count was significantly higher only at 1 month after splenectomy (P=0.039), the lymphocyte count remained at higher levels at 1 month (P=0.004), 3 months (P<0.001), and 6 months (P<0.001). The percentage of neutrophils in WBC was significantly higher than that of lymphocytes in WBC before splenectomy (P<0.05). In contrast to a significant decrease in the percentages of neutrophils in WBC at 1 month (P=0.033), 3 months (P<0.001), and 6 months (P=0.001) after splenectomy, those of lymphocytes in WBC significantly increased at 3 months (P<0.001) and 6 months (P=0.005; Fig. 1A). The NLR significantly decreased at 3 months (P=0.001) and 6 months (P=0.008; Fig. 1B).

Changes in CD4^+ and CD8^+ T cells and their naïve/memory subsets. Fig. 2A shows a representative flow cytometry profile of CD4^+ T cells, CD8^+ T cells, and their naïve/memory subsets in PBMCs before and after splenectomy. As shown in Fig. 2B, the frequency of CD4^+ T cells significantly decreased at 1 month (P=0.003), 3 months (P=0.001), and 6 months (P=0.016) after splenectomy, while that of CD8^+ T cells significantly increased at 3 months (P=0.004) and 6 months (P=0.014). In addition, the frequencies of the naïve (CCR7^+CD45RA^+) and central memory (CCR7^+CD45RA^-) subset of CD4^+ T cells significantly decreased at 1 month (P<0.001 and P=0.022, respectively), 3 months (P=0.010 and P=0.012, respectively), and 6 months (P=0.001 and P=0.023, respectively) after splenectomy. In contrast, that of the effector memory subset (CCR7^CD45RA^-) significantly increased at 1 month (P=0.001), 3 months (P<0.001), and 6 months (P=0.001; Fig. 2C).

Similarly, in CD8^+ T cells, the frequencies of the naïve (CCR7^CD45RA^+) and central memory (CCR7^CD45RA^-) subset significantly decreased at 1 month (P=0.007 and P=0.017, respectively), 3 months (P=0.010 and P=0.018, respectively), and 6 months (P=0.008 and P=0.008, respectively) after splenectomy, whereas that of the effector memory subset (CCR7^CD45RA^-) significantly increased after 1 month (P=0.003), 3 months (P=0.017), and 6 months (P=0.011; Fig. 2D).

Changes in γδ T, NKT, and NK cells. We also investigated the frequencies of γδ T, NKT, and NK cells among PBMCs before and after splenectomy. Fig. 3A shows a representative flow cytometry profile of γδ T, NKT and NK cells. As shown in Fig. 3B, the frequency of γδ T cells (CD3^- TCR γδ^+) significantly increased at 1 month (P=0.039) and 3 months (P=0.008) after splenectomy. In the same manner, the frequency of NKT cells (CD3^-CD56^-) tended to increase after 1 month (P=0.064) and 3 months (P=0.007; Fig. 3C). However, NK cells (CD3^-D56^-) showed a significant increase after 1 month (P=0.010), but not at any other time points (3 months, P=0.134; 6 months, P=0.210; Fig. 3D). The frequency of the CD56^+CD16^+ NK cell subset tended to increase at 1 month (P=0.052), 3 months (P=0.017), and 6 months (P=0.070) after splenectomy, whereas that of the
CD56<sup>bright</sup>CD16<sup>dim</sup> NK cell subset tended to decrease after 1 month (P=0.023), 3 months (P=0.068), and 6 months (P=0.069; Fig. 3E). We observed significant changes in γδ T, NKT, and NK cells only at the earlier two time points (1 and 3 months), suggesting that they might represent a transient, but not continuous, response to splenectomy.

Changes in Treg cells and MDSC. The frequencies of inhibitory immune cell subsets, including Treg cells and MDSCs, were further examined in PBMCs before and after splenectomy. Fig. 4A shows a representative flow cytometry profile of Treg cells. As shown in Fig. 4B, the frequency of Treg cells (CD4<sup>+</sup>CD25<sup>+</sup>FoxP3<sup>+</sup>) among PBMCs transiently decreased 3 months (P=0.045) after splenectomy, but not at the other time points (1 month, P=0.782; 6 months, P=0.416). Fig. 4C shows a representative flow cytometry profile of granulocytic MDSCs. As shown in Fig. 4D, the frequency of granulocytic MDSCs (CD11b<sup>+</sup>CD15<sup>+</sup>CD33<sup>+</sup>) was significantly lower at 3 months (P=0.022) and 6 months (P=0.045) after splenectomy. In contrast, the frequency of monocytic MDSCs (CD14<sup>+</sup>HLA-DR<sup>−/low</sup>) was not significantly affected (data not shown).

Evaluation of T-cell responses to viral- and tumor-associated antigens. To evaluate the effects of splenectomy on immune function, we examined T-cell responses to viral-associated (n=8) and tumor-associated (n=5) antigens using an IFN-γ ELISPOT assay with PBMCs before and after splenectomy. Fig. 5A and B show representative results of the assay in response to both viral- and tumor-associated antigens. In five of eight patients with liver cirrhosis, PBMCs after splenectomy showed higher numbers of IFN-γ-producing cells after stimulation with the viral-associated antigen peptide pool (CEF) compared with those before splenectomy. As shown in Fig. 5C, the spot numbers of CEF-specific cells after 6 months of splenectomy were significantly higher than those before splenectomy (P=0.031). In addition, when PBMCs were stimulated with the tumor-associated antigen peptide pool (KRM-20), more IFN-γ-producing T cells were detected after splenectomy in two of five patients with cirrhosis. As shown in Fig. 5C, the spot numbers of KRM-20-specific cells after 6 months of splenectomy tended to be higher than those before splenectomy, although not statistically significant (P=0.125), possibly due to the small sample size and the high standard deviation.
Discussion

The current study demonstrated that splenectomy significantly increased the frequencies of immune cells with effector properties such as CD8$^+$ T cells, γδ T cells, NKT cells, and NK cells, but significantly decreased those with suppressive properties such as Treg cells and MDSCs. In addition, the immune responses against viral- and tumor-associated antigens were augmented after splenectomy. These findings suggest that splenectomy might ameliorate the impaired immune status in cirrhotic patients with hypersplenism.

The NLR is one of the markers used to identify systemic inflammation, which is associated with the development, progression, and prognosis of various benign and malignant diseases. A higher NLR reflects increased production and secretion of pro-inflammatory cytokines and vascular endothelial growth factor by neutrophils in the circulation, resulting in vascular invasion, seeding, and growth of malignant cells (13,14,19,20). For example, an elevated NLR has been reported to correlate with the tumor burden, recurrence, and survival in patients with colorectal cancer, colorectal liver metastasis, HCC, gastric cancer, renal cancer, and pancreatic cancer (13,14,19-21). The NLR has also been found to reflect the severity of other diseases, including sepsis, cardiovascular abnormalities, and diabetes mellitus (22). The present study showed that the NLR was significantly lower at 3 and 6 months after splenectomy. Similarly, reduction of the NLR, which was correlated with better prognosis, was observed after splenectomy in our previous study of patients with HCC (7).
Patients with cirrhosis have a higher CD4^+ /CD8^+ T cell ratio because of an increase in CD4^+ T cell frequency together with a decrease in CD8^+ T cell frequency (3). Since CD8^+ T cells play crucial roles in anti-infection and anti-tumor immune responses, patients with liver cirrhosis are considered to be immunocompromised in part due to reduced CD8 cells, which might lead to higher incidences of bacterial infection and HCC development/recurrence (3,4). The current study demonstrated that splenectomy lowered the CD4^+ /CD8^+ T-cell ratio by decreasing the CD4^+ T-cell frequency and increasing the CD8^+ T-cell frequency, which may potentially enhance the anti-infection and anti-tumor immune responses. In addition, we detected an increase in effector memory T-cell subsets and a reduction in naïve and central memory subsets after splenectomy. Naïve T cells initiate immune responses to new antigens, while memory T cells (central memory and effector memory cells) respond to previously encountered antigens (23). Central memory cells are restricted to the lymphoid tissue and blood, whereas effector memory cells broadly migrate between peripheral tissues, blood, and the spleen, and provide immediate protection against pathogens (24). Such changes in naïve/memory T-cell subsets in this study might have resulted from accelerated antigen-specific immune responses after splenectomy (23,25,26). Indeed, in the current study, T-cell-mediated IFN-γ production in response to viral- and tumor-associated antigens was shown to increase after splenectomy in some patients with cirrhosis. Similarly, it has been suggested that splenectomy in patients with cirrhosis might improve their impaired immune status by increasing IFN-γ production and reducing programmed cell death protein 1 (PD-1)-expression in peripheral CD4^+ T cells (27,28).

This is the first study to show a decrease in MDSCs after splenectomy in patients with cirrhosis. Recent studies have shown that MDSCs are closely associated with suppressive immune conditions (29) and that a high MDSC count before treatment is a negative prognostic factor for patients with HCC undergoing hepatic arterial infusion chemotherapy (30). In tumor-bearing animal models, immature myeloid cells, including MDSCs, were found to accumulate in the spleen, the removal of which inhibited the growth and progression of liver cancer and prolonged animal survival (31). Because MDSCs also inhibit cytotoxic T-cell activation (25,26,31), the reduced number of MDSCs in our patients after splenectomy might enhance immune competence.

The current study also demonstrated for the first time that CD4^+CD25^+FoxP3^+ Treg cells decreased after splenectomy in the peripheral circulation of patients with cirrhosis. Treg cells are another subset of immune suppressors that play an
important role in the development and progression of various diseases such as autoimmune disease, viral infection, and cancer (29). In a previous study, the frequency of Treg cells was elevated in patients with HCV+ liver cirrhosis (32). A higher frequency of Treg cells was shown to be significantly associated with enhanced tumor growth of HCC in patients undergoing intra-arterial chemotherapy (33). The spleen is also reportedly a major source of Treg cells in patients with splenomegaly (34). MDSCs, the numbers of which decreased after splenectomy in this study, promote de novo development and induction of Treg cells (29). Considering all of these findings, splenectomy appears to enhance the immune response through reduction of Treg cells and MDSCs in the spleen and peripheral blood.

In contrast, NK cells play an important role in anti-viral and anti-tumor defenses. NK cells perform various effector functions, including production of IFN-γ, activation of tumor antigen-specific CD8+ T cells, and initiation of perforin-mediated cytolysis of tumor cells (35,36). Other researchers have reported that in patients with HCV+ liver cirrhosis, NK cells decreased in number and were correlated with HCC development (37), and that HCV downregulated NK cell function via viral serine protease NS3 (38). In the current study, the frequency of NK cells significantly increased 1 month after splenectomy. In particular, the number of cells in the CD56dim NK cell subset, which exhibited more powerful cytotoxic activity than CD56bright NK cells (39), was significantly elevated after splenectomy. Splenectomy in HCV-positive patients with cirrhosis augmented the activity of NK cells (36). A significant increase in both the percentage and activity of NK cells after splenectomy has also been reported by other researchers (40). Because MDSCs reportedly suppress the production of IFN-γ by NK cells (41), it is possible that reduction of MDSCs after splenectomy may increase the NK cell number and function to augment protective immunity.

Recently, oral thrombopoietin receptor agonists have been reported to stimulate thrombopoiesis, and potentially improve pancytopenia in cirrhotic patients (42,43). They transiently increase platelet counts for a limited period (42,43), while splenectomy in cirrhotic patients improve hypersplenism, including increase of platelet and white blood cell counts, for a long period (7,8). In addition, splenectomy not only has the clinical benefits, such as improvement of liver function and reduction of portal venous pressure (7-11), but also may contribute to immunological benefits, based on our study and others (27,28). It would be interesting to examine immune status after treatment with oral thrombopoietin receptor agonists and compare it with that after splenectomy in cirrhotic patients.

Partial splenic embolization (PSE) via catheter intervention is also known to be an effective alternative to splenectomy that is less invasive than surgery. Interestingly, Matsukiyo et al recently reported that PSE not only improve leukopenia and thrombocytopenia but also induce activation of CD4+ T cells, including Th1 and Th2 cells, in patients with cirrhosis and thrombocytopenia (44). Because the current study did not address Th1 and Th2 cytokine expression and their balance in CD4+ T cells, it would be interesting to examine them before and after splenectomy and compare them with those after PSE in cirrhotic patients in future studies. Matsukiyo et al also demonstrated that Treg cells, which were identified as CD4+CD25highCD127low, did not significantly change after PSE (44), whereas we showed that Treg cells, which were identified as CD4+CD25highFoxP3+, decreased after splenectomy in patients with cirrhosis. Such discrepancy might be explained by the different definition of Treg cells, as previously reported (45).
In summary, the current study suggested that splenectomy might ameliorate the impaired immune status of patients with cirrhosis, possibly by reducing suppressive cell fractions and enhancing the effector cell population and function. To our knowledge, this is the first study to comprehensively examine the effects of splenectomy on the NLR as well as the immunological phenotypes and responses in peripheral blood. However, this study has several limitations. First, this was a small study comprising patients with different disease states. Second, although changes in the immune cell phenotypes were precisely characterized, the immune functions of each cell subset were not examined in detail. Third, the enrolled patients were followed only for a limited period of time after splenectomy. Further studies with more patients and longer follow-ups are required.

Acknowledgements

The authors would like to thank Ms Yuri Kasama-Kawaguchi (Kurume University, Kurume, Japan) for her technical assistance.

Funding

No funding was received.

Availability of data and materials

The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

Authors’ contributions

TO and TS planned and designed the study. YH, TO, TS and TY performed the experiments and data analysis. YH, TO and KO treated the patients and acquired the clinical data and samples. KI, HT and KO provided scientific advice and interpreted the data. YH, TO and TS interpreted the data and drafted the manuscript. All authors read and approved the final manuscript.

Ethical approval and consent to participate

The present study was conducted in accordance with the provisions of the Declaration of Helsinki and was approved by the Institutional Review Board at Kurume University Hospital (Kurume, Japan). Before surgery, possible undesirable outcomes were explained to all patients involved in the study, and written informed consent was obtained from them.

Patient consent for publication

Not applicable.

Competing interests

Kyogo Itoh has stock ownership of BrightPath Biotherapeutics Co., Ltd., and received research funding from Taiho Pharmaceutical Co., Ltd. Takuto Yamashita is an employee of BrightPath Biotherapeutics Co., Ltd. The other authors declare that they have no competing interests.

References


